DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Study results/Miscellaneous
Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives
Reimbursement for Outpatient Care
2021-01-12 / 09:48
The issuer is solely responsible for the content of this announcement.
Berlin, 12 January 2021. Seed implantation for prostate cancer is now to be
reimbursed as an outpatient treatment by public health insurances in
Germany. This was decided by the Federal Joint Committee (G-BA) with effect
from January 8, 2021.
Seed implantation or so called LDR brachytherapy is an organ-preserving,
minimally invasive radiation procedure. In this procedure, millimeter-sized,
low-level radioactive titanium tubes are inserted into the prostate while
protecting the surrounding tissue. Compared to other treatment options, such
as removal of the prostate or external radiation therapy, brachytherapy has
a different side effect profile that is often more beneficial for the
patient.
"We are pleased that the treatment costs of seed brachytherapy for prostate
cancer are now to be covered by the public health insurance funds, both on
an inpatient and outpatient basis," explains Dr. Harald Hasselmann, member
of the Executive Board of Eckert & Ziegler AG and responsible for the
Medical segment. "In its summary assessment, the G-BA recognizes the benefit
of the method as sufficiently proven and its medical necessity as given."
"As a result of the consideration of benefit and medical necessity,
brachytherapy for localized prostate cancer can achieve a PSA-based
recurrence-free survival comparable to other curative therapies (radical
prostatectomy, percutaneous radiotherapy). The side effect profile of LDR
brachytherapy shows advantages in terms of preservation of continence and
sexual function as well as bowel function," summarizes the G-BA in its
overall assessment of interstitial brachytherapy for localized prostate
cancer with a low risk profile.
There are approximately 473,000 new cases of prostate cancer in Europe each
year (Globocan, 2020). In Germany, inpatient seed brachytherapy has been
included in the reimbursement catalog of health insurance companies since
2004. Eckert & Ziegler BEBIG is the European market leader for seeds and
produces them at its Berlin site.
*About Eckert & Ziegler. *
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800
employees, is one of the world's largest providers of isotope-related
components for radiation therapy and nuclear medicine. Eckert & Ziegler
shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
*Contributing to saving lives.*
Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com [1]
2021-01-12 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 1159971
End of News DGAP News Service
1159971 2021-01-12
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f8525ca55295fb1907527afac25224be&application_id=1159971&site_id=vwd&application_name=news
(END) Dow Jones Newswires
January 12, 2021 03:48 ET (08:48 GMT)